Hospital drug discounts now capped at patient cost-sharing; tighter rules to prevent profit-taking

What it does

This bill reforms the 340B drug pricing program, which allows certain healthcare entities (hospitals, clinics, safety-net providers) to purchase drugs at steep discounts for their patients. The bill tightens eligibility rules for who counts as a 'patient' eligible for 340B pricing, restricts how hospitals can use off-campus facilities and contract pharmacies, requires hospitals to cap patient out-of-pocket costs on 340B drugs, and adds enforcement mechanisms including civil penalties and audits. The net effect is to narrow the program's scope, reduce potential for abuse or profit-taking by covered entities, and ensure discounted drugs actually reach low-income patients rather than being resold or used for non-qualifying patients.

Why we flagged it

The bill's core function is to tighten eligibility and compliance rules in the 340B program and mandate patient affordability protections. It is not a deregulation or a carve-out; it is a regulatory tightening aimed at preventing abuse and ensuring the program serves its intended beneficiaries.

What the text implies

• Hospitals and large nonhospital covered entities (those with >$1B annual revenue or affiliated with hospitals) face new restrictions on contract pharmacy use and mail-order dispensing, potentially reducing their operational flexibility and profit margins on 340B drugs.
• The bill's 'specified nonhospital covered entity' definition (>$1B revenue or hospital-affiliated) may push smaller safety-net providers to consolidate or affiliate with hospitals to maintain program access, concentrating market power.
• Child-site registration requires Medicare cost-report documentation and charity-care thresholds; facilities that cannot meet these may lose 340B access, potentially reducing drug availability in underserved areas if those facilities are the only providers.
• Contract pharmacies face escalating penalties (first violation: repayment + interest; second: $3,000 per claim + repayment; third: removal for ≥2 years), creating high compliance burden and potential market exit for smaller pharmacy chains.
• The bill requires HHS to issue guidance within 180 days and final regulations within 90 days on patient affordability and compliance procedures; implementation timelines are tight and may create interim uncertainty for covered entities and pharmacies.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Low-income and uninsured patients gain enforceable caps on out-of-pocket costs for 340B drugs (free for those below poverty line, $35–$50 caps for others), and the bill closes loopholes that allowed hospitals to claim discounts on drugs for non-qualifying patients or resell them. Hospitals and other covered entities lose the ability to use 340B as a profit center; they must now demonstrate genuine patient need and afford care. The tighter rules reduce fraud and waste in a program designed to ser

Who stands to gain

• Low-income and uninsured patients (capped out-of-pocket costs)
• Safety-net hospitals and clinics (if they comply, they retain 340B access and avoid penalties)

Named in the bill

340B program, Covered entities (hospitals, FQHCs, safety-net providers), Contract pharmacies, Mail-order pharmacies, Manufacturers of covered outpatient drugs, Medicaid programs, HHS Office of Inspector General, Federal poverty guidelines, Medicare cost reports, Public Use Microdata Areas (Census Bureau)

Where it stands

1 cosponsor: 1 Republicans.

• Sep 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 10, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

20 lobbying clients named this bill on 25 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $32,910,506 in lobbying spend. A filing names 19 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

Buddy Carter, the sponsor, reported $988,325 in PAC receipts in the 2026 cycle. $16,500 of that came from 3 PACs tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• American Hospital Association — $4,470,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Pfizer Inc. — $1,720,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.